@article {Tang2022.03.31.22273263, author = {Sunny X. Tang and Katrin H{\"a}nsel and Yan Cong and Amir H. Nikzad and Aarush Mehta and Sunghye Cho and Sarah Berretta and Leily Behbehani and Sameer Pradhan and Majnu John and Mark Y. Liberman}, title = {Latent Factors of Language Disturbance and Relationships to Quantitative Speech Features}, elocation-id = {2022.03.31.22273263}, year = {2022}, doi = {10.1101/2022.03.31.22273263}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background and Hypothesis Quantitative acoustic and textual measures derived from speech ({\textquotedblleft}speech features{\textquotedblright}) may provide valuable biomarkers for psychiatric disorders, particularly schizophrenia spectrum disorders (SSD). We sought to identify cross-diagnostic latent factors for speech disturbance with relevance for SSD and computational modeling.Study Design Clinical ratings for speech disturbance were generated across 14 items for a cross-diagnostic sample (N=343), including SSD (n=97). Speech features were quantified using an automated pipeline for brief recorded samples of free-speech. Factor models for the clinical ratings were generated using exploratory factor analysis, then tested with confirmatory factor analysis in the cross-diagnostic and SSD groups. Relationships among factor scores, speech features and other clinical characteristics were examined using network analysis.Study Results We found a 3-factor model with good fit in the cross-diagnostic group and acceptable fit for the SSD subsample. The model identifies an impaired expressivity factor and two interrelated disorganized factors for inefficient and incoherent speech. Incoherent speech was specific to psychosis groups, while inefficient speech and impaired expressivity showed intermediate effects in people with nonpsychotic disorders. Network analysis showed that the factors had distinct relationships with speech features, and that the patterns were different in the cross-diagnostic versus SSD groups.Conclusions We report a cross-diagnostic 3-factor model for speech disturbance which is supported by good statistical measures, intuitive, applicable to SSD, and relatable to linguistic theories. It provides a valuable framework for understanding speech disturbance and appropriate targets for modeling with quantitative speech features.Competing Interest StatementSXT is a consultant for Neurocrine Biosciences and North Shore Therapeutics, received funding from Winterlight Labs, and holds equity in North Shore Therapeutics. The other authors have no conflicts of interest.Funding StatementThis project was supported by the Brain and Behavior Research Foundation Young Investigator Award (SXT) and the American Society of Clinical Psychopharmacology Early Career Research Award (SXT). Data for a portion of the participants (n=210) was collected in partnership with, and with financial support from, Winterlight Labs, Inc, but the conceptualization for this project, computation of speech features, and analyses were completed independently.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the Feinstein Institutes for Medical Research gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll metadata, code for analysis, and resources for duplicating our factor score calculations are available at: https://github.com/STANG-lab/Analysis/tree/main/Factor-network}, URL = {https://www.medrxiv.org/content/early/2022/04/01/2022.03.31.22273263}, eprint = {https://www.medrxiv.org/content/early/2022/04/01/2022.03.31.22273263.full.pdf}, journal = {medRxiv} }